A pill that can help prostate cancer patients live about five months longer was launched in Britain Wednesday.
The drug, Zytiga, developed by British scientists, can increase life expectancy even in men with advanced, aggressive cancers, the express.co.uk reported.
The drug cost 3,000 pounds and is yet to be approved for NHS (National Health Service) prescription.
Until then, patients can ask their doctors, or approach the Cancer Drugs Fund or their Primary Care Trust, for the drug.
Zytiga works by cutting off the tumour’s supply of testosterone, stopping it from growing.
It can be used in up to 80 percent of patients with drug-resistant prostate cancer who have already tried anti-hormonal therapies and chemotherapies, the Express said.